Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Empagliflozin by Boehringer Ingelheim International for Pulmonary Arterial Hypertension: Likelihood of Approval
Empagliflozin is under clinical development by Boehringer Ingelheim International and currently in Phase II for Pulmonary Arterial Hypertension. According to...